Trazodone - OWP Pharmaceuticals
Latest Information Update: 12 Jul 2023
At a glance
- Originator OWP Pharmaceuticals
- Class Antidepressants; Erectile dysfunction therapies; Piperazines; Pyridines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action 5-HT2C serotonin receptor antagonists; Serotonin 5-HT2A receptor antagonists; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Major depressive disorder
Most Recent Events
- 12 Jul 2023 Clinical trials in Major depressive disorder in USA (PO) (OWP Pharmaceuticals pipeline, July 2023)
- 13 Jan 2023 Preclinical trials in Major depressive disorder in USA (PO) (OWP Pharmaceuticals pipeline, January 2023)
- 30 Nov 2022 OWP Pharmaceuticals files for patent protection with United States Patent and Trademark Office fororal formulation of Trazodone in USA